Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Chief Medical Officer | March 04, 2021 | March 05, 2021 |
| KAZIA THERAPEUTICS LTDKZIA · Entity 6537 | Chief Executive Officer | January 08, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date March 04, 2021 · Filed March 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2021-03-04 | Direct | 330,000 |
Reported balance
After 2021-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-04 · Grant · Acquired 330,000 · Balance 330,000 F1: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.
KAZIA THERAPEUTICS LTD
Report date January 08, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 | Direct | 500,000 |
Reported balance
After 2026-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 500,000 · Balance 500,000 F1: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 150,000 |
Reported balance
After 2026-01-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-08 · Grant · Disposed 150,000 · Balance 150,000 F2: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.
F2: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Jul 8, 2026 20:59 UTC | KAZIA THERAPEUTICS LTD KZIA · Entity 6537 | GrantRestricted Share Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 2 Friend John E. II · CIK 0001704021 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: ADSs · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. F2 · derivative.exercise_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. F2 · derivative.expiration_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:59 UTC | KAZIA THERAPEUTICS LTD KZIA · Entity 6537 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 1 Friend John E. II · CIK 0001704021 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: ADSs · 500,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:46 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 330,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-21-032851 · tm218888d1_4.xml · derivative · entry 1 Friend John E. II · CIK 0001704021 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2021-03-04 F1 · derivative.exercise_date: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 10:06 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001104659-20-080841 · tm2023996d2_4.xml · derivative · entry 1 Friend John E. II · CIK 0001704021 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option shall vest in three equal installments beginning on the first anniversary of the date of grant. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:48 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 63,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053876 · tv504840_form4.xml · derivative · entry 1 Friend John E. II · CIK 0001704021 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 29,820 shares, which vest as to all shares on the first anniversary of the grant date, and a contingent grant of 33,180 shares, which are subject to the following conditions: (i) approval by Cellectar?s stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation?s 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest over a period of three years from the grant date, vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 22:30 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-020952 · v464509_form4.xml · nonDerivative · entry 1 Friend John E. II · CIK 0001704021 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Common stock grant that vests in equal annual increments over a period of three years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.